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OBJECTIVE—Induction of mixed or complete chimerism via
hematopoietic cell transplantation (HCT) from nonautoimmune
donors could prevent or reverse type 1 diabetes (T1D). In clinical
settings, HLA-matched HCT is preferred to facilitate engraftment
and reduce the risk for graft versus host disease (GVHD). Yet
autoimmune T1D susceptibility is associated with certain HLA
types. Therefore, we tested whether induction of mixed chime-
rism with major histocompatibility complex (MHC)-matched
donors could reverse autoimmunity in the NOD mouse model
of T1D.
RESEARCH DESIGN AND METHODS—Prediabetic wild-type
or transgenic BDC2.5 NOD mice were conditioned with a radiation-
free GVHD preventative anti-CD3/CD8 conditioning regimen and
transplanted with bone marrow (BM) from MHC-matched or
mismatched donors to induce mixed or complete chimerism. T1D
development and thymic deletion of host-type autoreactive
T-cells in the chimeric recipients were evaluated.
RESULTS—Induction of mixed chimerism with MHC-matched
nonautoimmune donor BM transplants did not prevent T1D in
wild-type NOD mice, although induction of complete chimerism
did prevent the disease. However, induction of either mixed or
complete chimerism with MHC-mismatched BM transplants
prevented T1D in such mice. Furthermore, induction of mixed
chimerism in transgenic BDC2.5-NOD mice with MHC-matched
or -mismatched MHC II
2/2 BM transplants failed to induce thy-
mic deletion of de novo developed host-type autoreactive T-cells,
whereas induction of mixed chimerism with mismatched BM
transplants did.
CONCLUSIONS—Induction of mixed chimerism with MHC-
mismatched, but not matched, donor BM transplants re-establishes
thymic deletion of host-type autoreactive T-cells and prevents T1D,
with donor antigen-presenting cell expression of mismatched MHC
II molecules being required. Diabetes 60:555–564, 2011
T
ype 1 diabetes (T1D) is an autoimmune disease
in which autoreactive T-cells attack the insulin-
secreting islet b-cells and result in insulin de-
ﬁciency and hyperglycemia (1–3). NOD mouse is
still the best animal model for T1D, although the autoim-
mune abnormality in NOD mice does not totally reﬂect the
abnormality in T1D patients (4–6). The autoimmunity in
NOD mice and T1D patients is associated with particular
major histocompatibility complex (MHC) or HLA loci such
as IAb
g7 or HLA-DR (7–9). This particular genetic back-
ground is associated with central tolerance defects, in
which autoreactive thymocytes are resistant to negative
selection (10–12), as well as peripheral tolerance defects
(13–17).
Transgenic expression of protective MHC II molecules
in the thymus has been shown to prevent T1D de-
velopment in mice (18–20). However, this approach cannot
readily be translated to humans. Immunomodulation
therapies such as administration of anti-CD3 have been
shown to reverse new-onset T1D in mouse or ameliorate
new-onset T1D in patients via induction of regulatory T-
cells (21–25). However, the therapeutic beneﬁt in patients
appears to be limited in terms of duration (25). This indi-
cates modulation of peripheral tolerance may not be suf-
ﬁcient for stable re-establishment of immune tolerance in
T1D patients, because the defective thymus may con-
stantly export autoreactive T-cells, which can overwhelm
peripheral tolerance mechanisms. Therefore, a therapy
that can re-establish both central and peripheral tolerance
in T1D patients would appear optimal as a means to re-
verse the autoimmunity associated with T1D.
Indeed, autoimmune diseases such as T1D arise from
abnormality in the immuno-hematological compartment,
and a replacement of the system from a nonautoimmune
individual can cure autoimmune T1D or vice versa (26).
Therefore, previous studies have proposed that induction
of mixed chimerism via hematopoietic cell transplantation
(HCT) may provide a curative therapy for autoimmune
diseases such as T1D (27). Although it was reported in-
duction of mixed chimerism with bone marrow (BM)
transplants from MHC-mismatched or MHC-matched non-
autoimmune donors was able to prevent T1D development
in NOD recipients conditioned with myelo- or non-
myeloablative total body irradiation (TBI) (28–32), as well
as in recipients conditioned with a radiation-free anti-CD3-
based regimen (33,34), the mechanisms whereby mixed
chimerism reverses such autoimmunity remain largely
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ORIGINAL ARTICLEFIG. 1. Mixed and complete chimerism with MHC-mismatched BM transplants both prevented T1D in NOD mice. Wild-type NOD mice were con-
ditioned with anti-CD3/CD8 (5 mg each) on days 210 and 25. On day 0, the conditioned mice were transplanted with graded doses of CD4
+ TCD
splenocytes and whole BM from wild-type C57BL/6 donors to induce chimerism (<20 3 10
6 each for the mixed, ;50 3 10
6 each for the complete
chimeras). Diabetes development was monitored weekly by both urine and blood glucose for up to 100 days. Thereafter, the recipient pancreas,
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the coexistence of donor- and host-type lymphocytes in
the periphery such as in the blood or spleen, but it remains
unclear whether the host-type cells in the mixed chimeric
recipients are de novo developed after HCT or residual
mature lymphocytes developed before HCT. In other
words, it is not clear whether mixed chimerism can me-
diate deletion of de novo developed autoreactive T-cells.
In addition, although MHC-matched HCT is preferred in
clinical settings, it is not yet clear whether induction of
mixed chimerism with MHC-matched donor transplants
can mediate thymic deletion of de novo developed host-
type autoreactive T-cells, because the defect in negative
selection is associated with particular MHC II loci (7–9).
In the current study, we identiﬁed true mixed chimeras
by measuring the donor and host-type T-cell precursors in
the thymus as well as immature B and myeloid cells in the
BM and we evaluated the impact of mixed and complete
chimerism with MHC-matched or mismatched donor BM
transplants.
RESEARCH DESIGN AND METHODS
Female NOD/LtJ and BDC2.5-NOD, wild-type C57BL/6, H-2
g7 C57BL/6, and
MHC II
2/2 C57BL/6 were purchased from the Jackson Laboratory (Bar Harbor,
ME). All mice were maintained in a pathogen-free room at City of Hope Re-
search Animal Facilities (Duarte, CA). Animal use procedures were approved by
our institutional committee.
Conditioning regimen and HCT. These procedures were described in our
previous publications (33,34).
Flow cytometry and cell depletion/enrichment. Flow cytometry staining
and analysis, CD11c enrichment, and CD4
+ T-cell depletion were performed as
described (33–35). Phycoerythrin (PE)–labeled BDC2.5-mimotope tetramer
(I-A
g7 AHHPIWARMDA) and control-tetramer (I-A
g7 PVSKMRMATPLLMQA)
were obtained from NIH Tetramer Facility (Atlanta, GA).
Pancreatic analysis. Analysis of insulitis and b-cell surface area was per-
formed as previously described (33).
Statisticalanalysis.ComparisonofT1Ddevelopmentwasevaluatedusingthe
log-rank test, and comparison of means was evaluated using unpaired two-
tailed Student t tests with Prism version 5 (GraphPad, San Diego, CA).
RESULTS
Induction of mixed and complete chimerism with
BM transplants from MHC-mismatched donors both
prevented insulitis and T1D development. It was
reported that induction of chimerism with BM cells from
MHC-mismatched nonautoimmune donors prevented T1D
development (28,30–34). However, it was not clear whether
those chimeric recipients had mixed or complete chime-
rism, because in those reports chimerism was measured
with peripheral blood mononuclear cells, and the mixed
chimerism could consist of residual host-type T-cells with-
out de novo developed host-type T-cells. To identify the true
mixed chimerism, de novo developed donor- and host-
type CD4
+CD8
+ thymocytes, as well as B220
+IgM
+ or
MAC1
+/Gr1
+ BM resident cells, needed to be measured.
Therefore, we used a recently reported radiation-free
and graft versus host disease (GVHD) preventative anti-
CD3/CD8-based condition regimen (33–36) to induce mixed
or complete chimerism by transplanting graded numbers of
donor cells. Accordingly, 6-week-old NOD mice (H-2k
d,
I-A
g7, CD45.1) were injected with anti-CD3 and anti-CD8
(5 mg/g each) on days 210 and 25. On day 0, the condi-
tioned mice were intravenously injected with graded num-
bers (5–50 3 10
6) of BM and CD4
+ T-depleted spleen cells
from MHC-mismatched C57BL/6 (H-2k
b,I - A
b,C D 4 5 . 2 )
donors. The control mice were given conditioning therapy
only. The recipients were checked for chimerism with
blood mononuclear cells and monitored weekly for T1D
development for up to 100 days after HCT. Thereafter, the
pancreas, spleen, BM, and thymus of the recipients and
control mice were harvested for evaluation of insulitis and
conﬁrmation of chimerism status.
Because we have reported that blood chimerism levels
become stable in NOD recipients conditioned with the
radiation-free anti-CD3-based regimen ;60 days after HCT
(34), and this notion was conﬁrmed with representative
recipients in the current study (Supplementary Fig. 1 and
Supplementary Table 1), we divided the recipients into
mixed and complete chimeras after that time point. We
found that the development of mixed and complete chi-
merism was associated with donor cell dose. In general,
recipients given .25 3 10
6 MHC-mismatched donor cells
all developed complete chimerism, and the majority of
recipients given ,20 3 10
6 donor cells developed mixed
chimerism as judged by analysis of donor- and host-type
T-cells, B-cells, and macrophages/granulocytes among blood
mononuclear cells. We also found that, 100 days after HCT,
66% (8 of 12) of the control mice, but none of the mixed or
complete chimeric recipients, developed T1D (P , 0.01,
Fig. 1A). Although almost all of the residual islets in con-
trol mice had severe insulitis, none of the islets in the
mixed and complete chimeric recipients had insulitis (P ,
0.01, Fig. 1B), although a small portion of them showed
very minor peri-insulitis (Fig. 1B) and there was no sig-
niﬁcant difference between mixed and complete chimeric
recipients (P . 0.5, Fig. 1B). A representative of the dif-
ferent types of insulitis is shown in Supplementary Fig. 2.
Furthermore, we conﬁrmed the status of chimerism by
examining the spleen, BM, and thymus of the recipients.
We observed that, in the mixed chimeras, more than one-
third of the T-cells, B-cells, macrophages, and granulocytes
TABLE 1
Percent donor- and host-type cells in spleen of mixed and
complete chimeras given MHC-mismatched BM transplants
TCRb
+ B220
+ MAC1/Gr1
+ CD11c
+
Mixed
Donor-type 63.1 6 13.8 51.6 6 17.0 55.9 6 14.6 29.1 6 21.2
Host-type 36.9 6 13.8 48.4 6 17.0 44.1 6 14.6 70.9 6 21.2
Complete
Donor-type 99.9 6 0 99.6 6 0.1 79.0 6 2.4 98.0 6 0.5
Host-type 0.1 6 0 0.4 6 0.1 21.1 6 2.4 2.0 6 0.5
Data are means 6 SE; n = 4. Donor-type cells were deﬁned as H-2k
b+,
and host-type cells were deﬁned as H-2k
b2.
spleen, BM, and thymus were harvested for evaluation of insulitis and chimerism status. There were 12 mice in each group combined from three
replicate experiments. A: T1D development curve after HCT. B: Percent insulitis (n =4 –6). C: One representative spleen cell FACS proﬁle of eight
recipients examined with anti-H-2Kb in each group. For DC patterns, spleens were digested with collagenase D and enriched using CD11c
microbeads. D: One representative FACS proﬁle of four recipients in each group examined with anti-CD45.2 and anti-CD45.1 for donor- or host-
type B220
+IgM
+ or Mac1
+/Gr1
+ cells in the BM. E: Representative FACS proﬁle of four recipients in each group examined with anti-H-2K
b and anti-
H-2K
d for donor- and host-type thymocytes.
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diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 557FIG. 2. Complete but not mixed chimerism with MHC-matched donor BM transplants prevented T1D. Wild-type NOD mice were conditioned with
anti-CD3/CD8 on days 210 and 25. On day 0, the conditioned mice were transplanted with CD4
+-TCD splenocytes and BM (50 3 10
6 each) from
MHC-matched H2-
g7 C57BL/6 mice to induce mixed chimerism. To induce mixed chimerism with TBI conditioning, wild-type NOD were conditioned
with 850cGy and transplanted with TCD BM (10 3 10
6). The control mice were given anti-CD3/CD8 conditioning only. Diabetes development was
monitored weekly by both urine and blood glucose for up to 100 days after HCT. Thereafter, the recipient pancreas, spleen, BM, and thymus were
harvested for evaluation of insulitis and chimerism status. A: Diabetes development curve after HCT (n = 12 for anti-CD3-conditioned chimeric
recipients; n = 18 for conditioning alone: n = 6 for TBI-conditioned chimeric recipients). B: Percent insulitis (n = 4 for anti-CD3-conditioned
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chimeras, less than 1% of the T- and B-cells were host-type,
although ;20% of the macrophage and granulocytes were
host-type (Fig. 1C and Table 1). We should point out that
those H-2
b2 cells may not be true host-type cells, because
we found that ;10% of the MAC-1/Gr-1
+ cells in the spleen
of C57BL/6 mice are H-2
b2 (Supplementary Fig. 3 and
Supplementary Table 2). The mixed chimeric recipients
had both donor- and host-type B220
+IgM
+ immature B-cells
and MAC1
+/Gr1
+ myeloid cells in the BM, whereas the
complete chimeras had only donor-type cells (Fig. 1D).
Consistently, the mixed chimeric recipients had both
donor- and host-type CD4
+CD8
+ thymocytes, and the com-
plete chimeric recipients had only donor-type but no host-
type thymocytes (Fig. 1E). Furthermore, after enrichment
of CD11c
+ cells from thymus, we observed donor CD11c
+
dendritic cells (DCs) in the thymus of both mixed and
complete chimeric recipients (Fig. 1E). This result is con-
sistent with a previous report showing that donor-type DCs
engraft in the thymus in the chimeric recipients as judged
by immunohistochemistry (IHC) staining (37).
Taken together, these results indicate that induction of
mixed chimerism with MHC-mismatched BM transplants is
as efﬁcient as induction of complete chimerism in pre-
vention of insulitis and T1D.
Induction of mixed chimerism with BM transplants
from MHC-matched donors did not prevent insulitis,
although induction of complete chimerism did. It was
reported by Beilhack et al. (29) that induction of mixed
chimerism in lethally irradiated NOD recipients with BM
cells from MHC-matched H-2
g7 donors prevents T1D, but it
was not clear whether those chimeric recipients were true
mixed chimeras with de novo developed host-type T-cells.
To clarify this issue, we performed a similar experiment by
transplanting H-2
g7 C57BL/6 (H-2k
d, I-A
g7, CD45.2) donor
T-cell depleted (TCD) BM cells (10 3 10
6) into lethally
irradiated NOD (H-2k
d, I-A
g7, CD45.1) recipients. In addi-
tion, we induced chimerism in anti-CD3/CD8-conditioned
NOD recipients by transplanting BM and CD4
+ T-depleted
spleen cells (50 3 10
6 each) from H-2
g7 C57BL/6 donors.
The control NOD mice were provided anti-CD3/CD8 con-
ditioning only. The recipients and control mice were
monitored for T1D development and checked for chime-
rism as described above.
We found that, consistent with the report of Beilhack
et al. (29), the total body irradiation (TBI)-conditioned
NOD recipients given TCD BM cells from MHC-matched
H-2g7 C57BL/6 donors appeared to have so called mixed
chimerism, as judged by the presence of both donor- and
host-type T- and B-cells among blood mononuclear cells
(data not shown), and no recipients developed T1D by 100
days after HCT, although ;61% (11/18) of control NOD
given conditioning only developed T1D (P , 0.01, Fig. 2A).
The anti-CD3/CD8-conditioned NOD recipients from BM
and CD4
+ T-depleted spleen cells also showed mixed chi-
merism among blood mononuclear cells (data not shown),
but ;17% (2/12) of them developed T1D by 100 days after
HCT, although there was still a signiﬁcant difference
compared with NOD mice given conditioning only (P ,
0.05, Fig. 2A). To further analyze the difference between
the TBI-conditioned and the anti-CD3/CD8-conditioned
chimeras, the pancreata of the chimeric recipients and
control mice were evaluated for insulitis and their spleen,
BM, and thymus were measured for chimerism. We found
that, although the TBI-conditioned chimeric animals had
little insulitis, the anti-CD3/CD8-conditioned chimeras had
severe insulitis (P , 0.01, Fig. 2B) and marked reduction
of b-cell surface as compared with the TBI-conditioned
recipients (P , 0.01, Fig. 2C). These results indicate that
insulitis is eliminated in TBI-conditioned but not in anti-
CD3-conditioned chimeras.
Furthermore, we found that, although there were both
donor- and host-type T-cells, B-cells, and macrophage/
granulocytes among the spleen cells of TBI-conditioned or
anti-CD3/CD8-conditioned chimeras, the donor-type cells
were dominant in the former, which was consistent with
the report of Beilhack et al. (29), but the host-type cells
were dominant in the latter (Fig. 2D and Table 2). In ad-
dition the immature B220
+IgM
+ B-cells and Mac-1
+/Gr-1
+
myeloid cells in the BM were almost all donor-type in the
TBI-conditioned recipients, although there were both donor-
and host-type cells in the anti-CD3/CD8-conditioned chi-
meras (Fig. 2E). Consistently, although there were both do-
nor- and host-type thymocytes in the TBI-conditioned
chimeras, there were only donor-type but no host-type
CD4
+CD8
+ thymocytes in the TBI-conditioned chimeras. In
contrast, both donor- and host-type CD4
+CD8
+ thymocytes
were present among the thymocytes of anti-CD3/CD8-con-
ditioned chimeras (Fig. 2F). Finally, there was only donor-
type CD11c
+ DCs in the thymus of TBI-conditioned chimeras,
although there were both donor- and host-type CD11c
+ DCs
in the anti-CD3/CD8 conditioned chimeras (Fig. 2F).
Taken together, the so-called mixed chimerism in lethally
irradiated TBI-conditioned chimeras consists of radiation-
resistant residual host-type but no de novo developed host-
type hematological cells, and they are actually complete
chimeras. In contrast, the mixed chimerism in anti-CD3/
CD8-conditioned recipients consists of both residual and de
novo developed host-type hematological cells, and they are
truly mixed chimeras. These results indicate that induction
of mixed chimerism with MHC-matched donor BM trans-
plants cannot prevent insulitis, although induction of com-
plete chimerism can.
Induction of mixed chimerism with BM transplants
from MHC-mismatched but not matched donors
resulted in thymic deletion of de novo developed
host-type autoreactive T-cells. We next tested whether
MHC-mismatched but not MHC-matched BM transplants
were able to restore thymic negative selection of auto-
reactive T-cells in the mixed chimeric NOD mice, using
T-cell receptor (TCR) transgenic BDC2.5-NOD mice (38).
In addition, we tested whether donor cell expression
of mismatched MHC II molecules was also required.
Accordingly, anti-CD3-conditioned BDC2.5-NOD (H-2k
d,
I-A
g7, CD45.1) mice were induced to develop mixed
chimerism by injecting whole BM cells (50 3 10
6) from
MHC-mismatched wild-type or MHC II
2/2 C57BL/6 (H-2k
b,
I-A
b, CD45.2) or MHC-matched H-2
g7 C57BL/6 (H-2k
d,
I-A
g7, CD45.2) donors. The chimerism was evaluated by
ﬂuorescence-activated cell sorting (FACS) analysis of blood
chimeric recipients; n = 6 for TBI-conditioned chimeric recipients and conditioning alone). C: Percent b-cell surface area as compared with total
pancreatic tissue surface area (n =4 –6). D: Representative FACS proﬁles showing spleen chimerism pattern 100 days after HCT (n = 12). For DC
patterns, spleens were digested with collagenase D and enriched using CD11c microbeads. E: Representative FACS proﬁles showing donor- or host-
type B220
+IgM
+ or Mac1
+/Gr1
+ cells in the BM (n =4 ) .F: Representative thymus chimerism pattern (n =6 –12).
J. RACINE AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 559mononuclear cells as described above (data not shown),
and the recipients were monitored for T1D development.
We found that although 75% (9/12) of control BDC2.5-
NOD mice given anti-CD3 conditioning only developed
T1D, none (0/12) of the mixed chimeric recipients with
MHC-mismatched BM showed T1D 160 days after HCT
(P , 0 . 0 1 ,F i g .3 A). In addition, although the control mice
had severe insulitis, the mixed chimeras with MHC-
mismatched wild-type BM showed no insulitis (P , 0.01),
although they showed mild peri-insulitis (Fig. 3B). It is
of interest that induction of mixed chimerism with MHC-
mismatched MHC II
2/2 or MHC-matched H-2
g7 donor BM
cells not only failed to prevent but markedly augmented
T1D development, as compared with the control BDC2.5-
NOD mice (P , 0.01, Fig. 3A). The mixed chimerism status
in the different group was conﬁrmed by ﬂow cytometry
analysis of the recipient spleen cells (Fig. 3C). These
results indicate that induction of mixed chimerism with
MHC-mismatched, but not MHC-matched, donor BM cells
can prevent T1D development in transgenic autoimmune
BDC2.5-NOD mice, and the expression of MHC II mole-
cules by the MHC-mismatched donor cells is required for
disease prevention.
We next tested whether there was a deletion of de novo
developed host-type autoreactive T-cells in the thymus
TABLE 2
Percent donor- and host-type cells in spleen of chimeras given
MHC-matched BM transplants
TCRb
+ B220+ MAC1/Gr1+ CD11c+
Anti-CD3 mixed
Donor-type 24.5 6 2.2 16.3 6 3.6 12.3 6 3.0 10.8 6 7.2
Host-type 75.5 6 2.2 83.8 6 3.6 87.7 6 3.0 89.2 6 7.2
TBI-mixed
Donor-type 79 6 0.9 98.5 6 0.1 99.0 6 0.2 97.1 6 2.8
Host-type 21.0 6 0.9 1.5 6 0.1 1.0 6 0.2 2.9 6 2.8
Data are means 6 SE; n = 4. Donor-type cells were deﬁned as
CD45.2, and host-type cells were deﬁned as CD45.2
2.
FIG. 3. Mixed chimerism with MHC-mismatched wild-type BM prevented T1D in transgenic BDC2.5-NOD mice. Transgenic BDC2.5-NOD mice were
conditioned anti-CD3 (5 mg) on day 27. On day 0, the conditioned mice were transplanted with BM cells (50 3 10
6) from MHC-mismatched wild-
type, MHC-mismatched MHC II
2/2 or MHC-matched H-2
g7 C57BL/6 donors to induce mixed chimerism. Diabetes development was monitored
weekly by both urine and blood glucose. A: Diabetes development curve after HCT (n = 12 for mice given conditioning alone or recipients given BM
cells from MHC-mismatched wild-type donors; n = 7 for recipients given MHC-mismatched MHC II
2/2 donor BM cells; n = 8 for recipients given
MHC-matched BM cells). B: Percent insulitis for recipients given MHC mismatched wild-type BM versus conditioning alone 120 days after
transplantation (n =4 ) .C: Representative spleen chimerism pattern (n =4 ) .D: Representative thymus chimerism pattern (n = 4).
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BM cells. We ﬁrst compared the percentage of donor- and
host-type thymocytes at CD4
2CD8
2, CD4
+CD8
+, and
CD4
+CD8
2 stages (Fig. 3D). BDC2.5-NOD mice are a CD4
+
T transgenic mouse line (38), thus, we did not evaluate
CD4
2CD8
+ thymocytes. We found that host-type thymo-
cytes were present among CD4
2CD8
2, CD4
+CD8
+, and
CD4
+CD8
2 in anti-CD3-conditioned control BDC2.5-NOD
mice without HCT as well as in the mixed chimeras given
MHC-mismatched MHC II
2/2 or MHC matched H-2
g7 donor
BM cells. In contrast, the host-type thymocytes in the
mixed chimeras given MHC-mismatched donor BM cells
were mainly present among CD4
2CD8
2 and CD4
+CD8
2
thymocytes, and they were nearly undetectable among
total CD4
+CD8
+ thymocytes (Fig. 3D). However, after
CD45.1
+ host-type cells were gated on, a small percentage
of CD4
+CD8
+ cells were detected in those mixed chimeric
recipients, although it was ;15-fold lower, as compared
with control BDC2.5 mice or the mixed chimeras given
MHC-mismatched MHC II
2/2 or MHC-matched donor BM
cells (P , 0.01, Fig. 4A). Interestingly, the reduction of the
percentage of CD4
+CD8
+ subset among host-type thymo-
cytes in the mixed chimeras given MHC-mismatched wild-
type donor BM cells was associated a more than 20-fold
increase of CD4
2CD8
2 subsets (P , 0.01, Fig. 4A). These
results indicate that host-type CD4
2CD8
2 thymocytes in
the mixed chimeras given MHC-mismatched donor BM
cells are prevented to develop into CD4
+CD8
+ stage.
Deletion of transgenic autoreactive thymocytes has
been reported to take place at CD4
2CD8
2 stage (39,40).
Thus we tested whether this is the case in the mixed
chimeric BDC2.5-NOD recipients, using I-A
g7-mimotope-
tetramer (BDC2.5-tetramer) to identify the autoreactive
BDC2.5 T-cells, as previously described (41). We found
that ;50% of the host-type CD4
2CD8
2 thymocytes in the
control BDC2.5 mice given anti-CD3-conditioning only
and the mixed chimeras given mismatched MHC II
2/2 or
MHC-matched donor BM cells were BDC2.5-tetramer
+
and that there was no signiﬁcant difference among the
three groups (Fig. 4A). In contrast, the BDC2.5-tetramer
+
cells among the host-type CD4
2CD8
2 thymocytes in the
mixed chimeras given MHC-mismatched wild-type donor
BM cells were reduced by approximately ﬁvefold as com-
pared with control BDC2.5-NOD mice (P , 0.01, Fig. 4A).
The yield of CD4
2CD8
2 BDC2.5-tetramer
+ thymocytes in
the former group was also reduced approximately ﬁve-
fold as compared with the latter (P , 0.01, Fig. 4C). In
addition, we found that, although the majority of the
residual host-type CD4
+CD8
+ or CD4
+ thymocytes and
CD4
+ splenic cells in the mixed chimeras given MHC-
mismatched wild-type donor BM cells were BDC2.5-
tetramer
+, which was similar to the control BDC2.5 mice
as judged by the percentage of BDC2.5-tetramer
+ cells
(Fig. 4B and data not shown), the yield of the CD4
+CD8
+
and CD4
+CD8
2 BDC2.5-tetramer
+ thymocytes as well as
the splenic CD4
+BDC2.5-tetramer
+ cells in those mixed
chimeras was markedly reduced as compared with the
control BDC2.5-NOD mice (P , 0.01, Fig. 4D–F). In con-
trast, induction of mixed chimerism with MHC-mismatched
MHC II
2/2 or MHC-matched donor BM cells did not result
in any reduction of the BDC2.5-tetramer
+ thymocytes or
splenic CD4
+ T-cells as compared with control BDC2.5-
NOD mice (Fig. 4C–F). These results indicate that induction
of mixed chimerism with MHC-mismatched wild-type donor
BM cells results in deletion of the de novo developed host-
type autoreactive BDC2.5 transgenic T at CD4
2CD8
2 stage,
and the deletion requires donor cell expression of mis-
matched MHC II molecules.
DISCUSSION
We believe this report represents novel ﬁndings by at least
three considerations. First was our noting that induction of
mixed chimerism with MHC-mismatched BM transplants
from nonautoimmune donors is as effective as induction
of complete chimerism in reversal of autoimmunity, eli-
mination of insulitis, and prevention of T1D. Second, in-
duction of mixed chimerism with MHC-matched BM
transplants failed to reverse autoimmunity, eliminate
insulitis, or prevent T1D development, although induction
of complete chimerism with the matched BM transplants
did. Finally, induction of mixed chimerism with MHC-
mismatched but not MHC-matched BM transplant results
in thymic deletion of de novo developed host-type auto-
reactive T-cells, and the deletion requires donor cell ex-
pression of MHC II molecules.
By measuring the chimerism of the de novo developed
thymocytes, we clearly demonstrated that induction of
mixed and complete chimerism with MHC-mismatched
BM transplants was equally effective in reversal of au-
toimmunity in NOD mice. Previous reports stated that
induction of so-called mixed chimerism in lethal or sub-
lethally irradiated NOD recipients with BM cells from
nonautoimmune donors prevented T1D (28,30–32). In
those reports, so called mixed chimerism was deﬁned by
coexistence of donor- and host-type lymphocytes in the
periphery of the chimeras, but it was not clear whether the
host-type lymphocytes were de novo developed after HCT
or residual host-type mature lymphocytes survived after
TBI-conditioning. In the current study, we conﬁrmed the
mixed or complete chimerism by the presence or absence
of de novo developed host-type CD4
+CD8
+ thymocytes as
well as BM cells. We observed that, although a low level
(i.e., ;1%) of host-type CD4
+ or CD8
+ lymphocytes were
present in the periphery and thymus of the complete chi-
meras, there were no detectable CD4
+CD8
+ thymocytes in
the complete chimeras. In contrast, both donor- and host-
type CD4
+CD8
+ thymocytes were present in the thymus,
and immature B- and myeloid cells were present in the BM
of the mixed chimeras. We found that, even in the true
mixed chimeric recipients with MHC-mismatched BM,
insulitis was eliminated and T1D was prevented. There-
fore, when MHC-mismatched donor BM transplantation is
used, induction of mixed chimerism is sufﬁcient for the
cure of T1D autoimmunity. We believe this is of clinical
signiﬁcance since it has been reported that mixed chi-
meras with MHC-mismatched BM transplants provide su-
perior immune function against infection (42,43).
Our studies also demonstrated that induction of mixed
chimerism with MHC-matched BM transplants from non-
autoimmune donors did not reverse autoimmunity or
eliminate insulitis, although induction of complete chime-
rism did. Consistent with the report of Beilhack et al. (29),
we observed that induction of chimerism in lethally irra-
diated NOD mice with TCD BM from MHC-matched H-2
g7
C57BL/6 donors resulted in so-called mixed chimerism.
However, we found that those chimeras did not have host-
type CD4
+CD8
+ thymocytes or host-type BM resident
B220
+IgM
+ or MAC1
+/GR1
+ cells, indicating that the host-
type T- or B-lymphocytes were not de novo developed.
Therefore, those so-called mixed chimeras were in fact
complete chimeras. In contrast, we found that the true
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Transgenic BDC2.5-NOD mice were conditioned anti-CD3 (5 mg) on day 27. On day 0, the conditioned mice were transplanted with BM cells (50 3
10
6) to induce mixed chimerism. Diabetes development was monitored weekly by both urine and blood glucose. Mice were analyzed for clonal
deletion of autoreactive T-cells at time of diabetes development, ;30–60 days after HCT. A: Representative FACS proﬁles showing clonal deletion
of autoreactive T-cells in the thymus. CD45.1
+ host-type thymocytes were gated on and shown in CD4 versus CD8, and CD4
2CD8
2 cells were then
gated and shown in histogram of BDC2.5-tetramer (solid line) versus control-tetramer (shaded area). B: Representative FACS proﬁles showing
residual tetramer
+ T-cells in the spleen. Host-type CD45.1
+CD4
+ splenocytes were gated on and shown in histogram of BDC2.5-tetramer
+ (solid
line) versus control-tetramer (shaded area) (n =4 ) .C–F: Yield of host-type tetramer
+ cells among CD4
2CD8
2, CD4
+CD8
+, and CD4
+CD8
2
thymocytes as well as CD4
+ splenocytes (n =4 ) .
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both donor- and host-type CD4
+CD8
+ thymocytes as well as
B220
+IgM
+ and MAC1
+/GR1
+ BM cells, and all of them had
severe insulitis and reduced b-cell quantity, indicating that
induction of mixed chimerism with MHC-matched donor BM
cells is not able to reverse T1D autoimmunity.
Using approaches similar to those that have been used
to evaluate thymic deletion of autoreactive T-cells medi-
ated by hematopoietic cell-derived antigen-presenting cells
(APCs) in previous publications (18,44,45), we demonstrated
that induction of mixed chimerism with MHC-mismatched
but not MHC-matched donor BM cells resulted in thymic
deletion of de novo developed host-type autoreactive T-cells
and that the deletion requires donor cell expression of
MHC II molecules. We observed that de novo developed
host-type autoreactive thymocytes in the mixed chimeric
BDC2.5-NOD transgenic mice given MHC mismatch but
not matched C57BL/6 BM cells were deleted before the
CD4
+CD8
+ thymocyte stage when they started to express
TCR, and the deletion required donor cell expression of
mismatched MHC II molecules. This indicates that auto-
reactive T-cell interaction with donor-type APC via TCR-
mismatched-MHC II complex play an important role in
thymic negative selection of autoreactive T-cells in the
mixed chimeras.
It was reported that the protection against T1D in
(BDC2.5-NOD x C57BL/6) F1 mice (H-2
g7/b) was not asso-
ciated with thymic deletion of the transgenic autoreactive
T-cells but rather associated with positive selection of non-
autoreactive T-cells expressing transgenic TCR coupling
with endogenous Vas (19). However, in the mixed chi-
meric BDC2.5 NOD mice, we found a marked reduction of
NOD host-type thymocytes that express autoreactive TCR
(Fig. 4), but no expansion of transgenic Vb4 coupling with
endogenous Vas (Supplementary Fig. 4). Therefore, positive
selection of nonautoreactive host-type T-cells by mis-
matched MHC II
b is unlikely to play a major role in re-
versal of autoimmunity in the mixed chimeric recipients.
It was reported that MHC II-positive hematopoietic cells
cannot mediate positive selection of CD4
+ T-lymphocytes
(46). It is not surprising that tolerization mechanisms in
mixed chimeras are different from F1 mice. In the chimeras,
the MHC II (I-A
b) molecules are expressed by donor-type
APC but not host-type thymic epithelial cells. The strong
signals from TCR interaction with allo-MHC II may induce
host-type thymocytes to go through apoptosis and result in
deletion. In contrast, in F1 mice, the MHC II (I-A
g7/b)m o l -
ecules are expressed by both thymic epithelial cells and
APCs, in which they may be able to positively select non-
autoreactive thymocytes with endogenous Va and unable
to mediate negative selection of autoreactive transgenic
thymocytes.
We should also emphasize the association between
failure in thymic deletion of the de novo developed host-
type autoreactive T-cells and the failure in elimination of
insulitis or prevention of T1D in the mixed chimeric
recipients given MHC-matched H-2
g7 donor BM trans-
plants. This indicates that re-establishing central tolerance
in autoimmune T1D recipients is critical for prevention
or reversal of autoimmunity. However, the signiﬁcant de-
lay of T1D onset in the mixed chimeric recipients given
MHC-matched H-2
g7 donor BM transplants also indi-
cates that peripheral tolerance mechanisms provided by
nonautoimmune H-2
g7 donor cells play a signiﬁcant role
in regulating T1D development, although it is not sufﬁ-
cient to fully prevent autoimmunity. It was reported that
non–MHC-associated loci from diabetes resistant mice
mediated peripheral tolerance in autoimmune NOD mice
(16,47).
In summary, we have identiﬁed the mechanisms wherein
induction of mixed chimerism re-establishes the critical
central tolerance in NOD mice. However, caution needs to
be considered with regards to whether similar mechanisms
operate in humans because of the far greater heterogeneity
of this disease in humans (48). We recently reported that
induction of mixed chimerism with MHC mismatched donor
BM transplants under the radiation-free and GVHD pre-
ventative anti-CD3-based conditioning regimen can reverse
new-onset T1D by augmenting residual b-cell expansion
(33) as well as provide immune tolerance to donor islets
(49). In addition, allogeneic donor T-cells in transplants
have been shown not to cause GVHD in humans with mixed
chimerism (50). Therefore, induction of mixed chimerism
under the radiation-free anti-CD3-based conditioning regi-
men may represent a curative therapy for severe T1D.
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